Navitoclax (ABT-263)

Catalog No.S1001

Navitoclax (ABT-263) Chemical Structure

Molecular Weight(MW): 974.61

Navitoclax (ABT-263) is a potent inhibitor of Bcl-xL, Bcl-2 and Bcl-w with Ki of ≤ 0.5 nM, ≤1 nM and ≤1 nM in cell-free assays, but binds more weakly to Mcl-1 and A1. Phase 2.

Size Price Stock Quantity  
In DMSO USD 400 In stock
USD 120 In stock
USD 200 In stock
USD 370 In stock
USD 970 In stock
Bulk Discount

Free Overnight Delivery on orders over $ 500
Next day delivery by 10:00 a.m. Order now.

Cited by 37 Publications

13 Customer Reviews

  • KP cells (A) and A549 cells (B) were treated with increasing doses of ATN-224 alone or with the BCL2 inhibitor ABT-263, and cell death (96 hours) was determined.

    J Clin Invest, 2014, 124(1): 117-28 . Navitoclax (ABT-263) purchased from Selleck.

    Cell lines are also resistant to dual inhibition of Bcl-xL and Bcl-2 by the inhibitor ABT-263 when dosed with NSC siRNA, but co-dosing ABT-263 with Mcl-1 siRNA decreases compound IC50 similar to that observed with WEHI-539. Representative curves for MDA-MB-157 are shown in f.

    Cell Death Differ, 2015, 10.1038/cdd.2015.73. Navitoclax (ABT-263) purchased from Selleck.

  • ABT-263 has a higher albumin binding affinity than ABT-737. The binding capacity of ABT-737 (solid lines) and ABT-263 (dotted lines) to HSA was investigated using a fluorescence polarization assay. A, to measure binding to site 2 on HSA-IIIA, dansyl sarcosine was used as a probe. In this assay the IC50 was 711 and 37μmol/L for ABT-737 and ABT-263, respectively. B, to measure binding to site 1 on HSA-IIA, dansyl L-glutamate was used as a probe. The IC50 was >1,000 and 145 μmol/L for ABT-737 and ABT-263, respectively.

    Clin Cancer Res 2010 16, 4217-4225. Navitoclax (ABT-263) purchased from Selleck.

    Clin Cancer Res 2010 16, 4217-4225. Navitoclax (ABT-263) purchased from Selleck.

  • Clin Cancer Res 2010 16, 4217-4225. Navitoclax (ABT-263) purchased from Selleck.

    Clin Cancer Res 2010 16, 4217-4225. Navitoclax (ABT-263) purchased from Selleck.

  • Clin Cancer Res 2010 16, 4217-4225. Navitoclax (ABT-263) purchased from Selleck.

    PLoS One 2011 6, e21980. Navitoclax (ABT-263) purchased from Selleck.

  • PLoS One 2011 6, e21980. Navitoclax (ABT-263) purchased from Selleck.

    PLoS One 2011 6, e21980. Navitoclax (ABT-263) purchased from Selleck.

  • Apoptosis induced by BCL2-inhibitors in P-glycoprotein expressing cells. MDCKII wild type or MDR1 cells were exposed to different concentrations of ABT-737 (C) or ABT-263 (D) for 24 h before apoptosis was assessed by flow cytometry using externalization of phosphatidylserine.

    Biochem Biophys Res Commun 2011 408(2), 344-9. Navitoclax (ABT-263) purchased from Selleck.

     

    (A) In vitro generated  Mcl-1-deleted  Arf-/- p185+ cells stably expressing the indicated constructs were treated with indicated doses of navitoclax (ABT-263) for 24 hours after which percent viable cells were determined (propidium iodide negative cells were scored as viable). Each point represents the average of three independent experiments and the error bars denote the SEM.  p185+ Arf-/- cells serve as a control.  (B) Arf -null p185+ cells were treated with navitoclax for 24 hours at indicated doses. Lysates were immunoprecipitated with anti-BIM antibody and immune complexes were resolved and western blotted for MCL-1, BCL-2 (human specific antibody), BCL-XL, BIM, PARP and Actin (loading control). Endogenous BIM serves as the control for equal immunoprecipitation. (E&F) p185+ Arf-/- cells were treated with indicated doses of navitoclax and/or  (E) IM or  (F) DAS for 24 hours after which percent viable cells was determined. Annexin-V and PI negative cells were scored as viable. IL-7 was added to a final concentration of 20 ng/mL.

    Navitoclax (ABT-263) purchased from Selleck.

  •  

    Human Ph+ cell lines:  (A)  OP-1 Ph+ B-ALL  (B) TOM1 Ph+ B-ALL and (C)  BV173 Ph+CML blast crisis cell lines were treated with navitoclax, imatinib (IM) or dasatinib (DAS) at indicated doses for 24 hours after which cell lysates were analyzed for expression of MCL-1, BCL-2, BCL-w, BFL-1 and BCL-XL.  For potentiation experiments, the percentage of viable cells was determined by Annexin-V and PI negativity.

    Navitoclax (ABT-263) purchased from Selleck.

Purity & Quality Control

Choose Selective Bcl-2 Inhibitors

Biological Activity

Description Navitoclax (ABT-263) is a potent inhibitor of Bcl-xL, Bcl-2 and Bcl-w with Ki of ≤ 0.5 nM, ≤1 nM and ≤1 nM in cell-free assays, but binds more weakly to Mcl-1 and A1. Phase 2.
Targets
Bcl-xL [1]
(Cell-free assay)
Bcl-2 [1]
(Cell-free assay)
Bcl-w [1]
(Cell-free assay)
<=0.5 nM(Ki) <=1 nM(Ki) <=1 nM(Ki)
In vitro

ABT-263 is structurally related to ABT-737; it is a disruptor of Bcl-2/Bcl-xL interactions with pro-apoptotic proteins. Overexpression of the prosurvival Bcl-2 family members is commonly associated with tumor maintenance, progression, and chemoresistance. [1] ABT-263 displays the protection afforded by overexpression of Bcl-2 or Bcl-xL with EC50 values of 60 nM and 20 nM, respectively. [1] A wide range of cellular activity is observed with ABT-263 having a 50% growth inhibition (EC50) of 110 nM against the most sensitive line (H146), whereas its activity in the least sensitive line (H82) results in an EC50 at 22 μM. All four cell lines with EC50 values of <400 nM (H146, H889, H1963, and H1417) are also highly sensitive to ABT-737, and the two most resistant lines (H1048 and H82) are similarly resistant to ABT-263. [2]

Cell Data
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID
EoL-1-cell M4TtTWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MVPJR|UxRTBwMEC2Olkh|ryP MmLsV2FPT0WU
MV-4-11 M1izNmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M3m5OWlEPTB;MD6wNVU5PiEQvF2= MYjTRW5ITVJ?
NKM-1 MVXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MVTJR|UxRTBwMEG2PVkh|ryP M1m3ZXNCVkeHUh?=
ML-2 MWrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M1rXPWlEPTB;MD6wNVk5OyEQvF2= MYTTRW5ITVJ?
BV-173 MoX0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? Mmr0TWM2OD1yLkCyN|E1KM7:TR?= NGrUUXhUSU6JRWK=
RS4-11 M165OGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M4nkSmlEPTB;MD6wNlU5PyEQvF2= MoPVV2FPT0WU
HL-60 NEC1S2ZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NE[0[Y5KSzVyPUCuNFI6ODhizszN M{HveXNCVkeHUh?=
KY821 MoTrS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MW\JR|UxRTBwMEK5O|Uh|ryP MmLwV2FPT0WU
ECC10 M{jJcWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NFHaNnZKSzVyPUCuNFM4QTJizszN MYnTRW5ITVJ?
NCI-H720 MofJS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NIWxeHpKSzVyPUCuNFQxOTFizszN M3rLW3NCVkeHUh?=
QIMR-WIL MX;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NGK1b4xKSzVyPUCuNFQzQDdizszN MlXqV2FPT0WU
KG-1 MX3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MVnJR|UxRTBwMES0PFYh|ryP MVHTRW5ITVJ?
TGW MnvmS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NUXGWoh4UUN3ME2wMlA1PjN|IN88US=> M{TVbXNCVkeHUh?=
ATN-1 NEnFdXlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MmHYTWM2OD1yLkC0O|M{KM7:TR?= M2Tx[XNCVkeHUh?=
RH-18 Ml:zS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M1[1PWlEPTB;MD6wOlA1QCEQvF2= M1LFRXNCVkeHUh?=
EW-18 M1Lnd2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MkLxTWM2OD1yLkC2PFQyKM7:TR?= MXPTRW5ITVJ?
NB17 M3fGbmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NIrycFZKSzVyPUCuNFcyOjRizszN NHjaSmFUSU6JRWK=
SK-NEP-1 MoX3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MVTJR|UxRTBwMEeyNVMh|ryP NILaSoNUSU6JRWK=
P12-ICHIKAWA NFrOWJBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NFfG[|lKSzVyPUCuNFc4PzhizszN M2\SS3NCVkeHUh?=
KARPAS-45 NFPpVotIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NW\YZodLUUN3ME2wMlA4QDF3IN88US=> M1jnOHNCVkeHUh?=
EW-3 MYPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MXPJR|UxRTBwMEiwOVMh|ryP NXLqcJNUW0GQR1XS
NB13 MYnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MXXJR|UxRTBwMEiyNFMh|ryP M4L2bHNCVkeHUh?=
NCI-H209 M1fvdGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MlTITWM2OD1yLkC4O|A1KM7:TR?= MXfTRW5ITVJ?
NCI-H1092 MlfnS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? Mk[wTWM2OD1yLkGwNlc2KM7:TR?= MoX4V2FPT0WU
NH-12 M1vnfWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MnXlTWM2OD1yLkGwO|Q1KM7:TR?= MXHTRW5ITVJ?
697 M3nrNGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M1fuc2lEPTB;MD6xNFg{QSEQvF2= Mom4V2FPT0WU
KE-37 MV;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NF63dJZKSzVyPUCuNVE{PyEQvF2= MVXTRW5ITVJ?
MOLT-4 MXjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MnHzTWM2OD1yLkG1NVY6KM7:TR?= NFvzNVlUSU6JRWK=
CHP-134 NI\UbHRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NFrkclhKSzVyPUCuNVY{ODZizszN M17KOnNCVkeHUh?=
D-283MED NXTFboxzT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NVO4SmdOUUN3ME2wMlE4Pjh4IN88US=> M1uxenNCVkeHUh?=
LU-135 MYPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MmrxTWM2OD1yLkG4OVUzKM7:TR?= MYPTRW5ITVJ?
LU-134-A NXi1cFRjT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MXTJR|UxRTBwMUi2O|Eh|ryP MmW2V2FPT0WU
EM-2 NH20eHlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MXXJR|UxRTBwMUm5NVgh|ryP MlvTV2FPT0WU
LU-139 NW[5PGVTT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MVzJR|UxRTBwMkC0PVgh|ryP NXjhN4p7W0GQR1XS
ALL-PO Mlf1S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MnflTWM2OD1yLkKxPVg5KM7:TR?= NFi0S4ZUSU6JRWK=
NB12 M3zHcGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NGnYW49KSzVyPUCuNlMyOTVizszN MWfTRW5ITVJ?
KP-N-YN MWDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M3\5PWlEPTB;MD6yN|U4OyEQvF2= MmC4V2FPT0WU
BEN NGDuRmpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MULJR|UxRTBwMkO5Olgh|ryP NVntU|FUW0GQR1XS
HCC1569 NV60Zox[T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MXrJR|UxRTBwMkWxNFYh|ryP M4rWUnNCVkeHUh?=
HuO9 NXzwRoR[T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NFu5TZZKSzVyPUCuNlY4OTVizszN MWnTRW5ITVJ?
WM-115 NXPPTHVrT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= Mn3NTWM2OD1yLkK3O|M5KM7:TR?= M4fiVnNCVkeHUh?=
CCRF-CEM M{nvbGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NGHzTYFKSzVyPUCuN|M2OjlizszN MnvPV2FPT0WU
IST-SL1 Mon3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MkLTTWM2OD1yLkO1N|Q{KM7:TR?= NIrRNXhUSU6JRWK=
BE-13 M1HYSmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MYrJR|UxRTBwM{[0OVkh|ryP MX\TRW5ITVJ?
COR-L88 NGPKVG1Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= Mk[2TWM2OD1yLkO2OVQh|ryP NEjTdHJUSU6JRWK=
DOHH-2 MmmzS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M1\GcGlEPTB;MD60NVAzOyEQvF2= M{PGfnNCVkeHUh?=
A704 MVrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MnnQTWM2OD1yLkSyOlch|ryP MV;TRW5ITVJ?
KNS-81-FD NF\0S5VIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M1LOdWlEPTB;MD60OFAyPyEQvF2= MlHxV2FPT0WU
RPMI-8226 NWLiNGdvT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NVG4N2lxUUN3ME2wMlQ2PjV{IN88US=> NVHjR2VXW0GQR1XS
TGBC24TKB NFm1b5JIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MoLDTWM2OD1yLkS1O|c5KM7:TR?= MkW3V2FPT0WU
NCI-H1304 NVXYOphyT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M3\sdmlEPTB;MD60OlE2PyEQvF2= MY\TRW5ITVJ?
MOLT-13 MWPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? Mn;1TWM2OD1yLkS2OlE{KM7:TR?= MoGzV2FPT0WU
EW-22 M2SwRWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M3nxc2lEPTB;MD60OlY4OSEQvF2= M3PuRXNCVkeHUh?=
MS-1 NFnWRpBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MWrJR|UxRTBwNE[5N|Mh|ryP MX;TRW5ITVJ?
RMG-I M4KwZ2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 Ml6wTWM2OD1yLkS5OFY1KM7:TR?= MkHvV2FPT0WU
NTERA-S-cl-D1 MmTTS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M4PtcmlEPTB;MD61NFAyQSEQvF2= NYHGS5Z3W0GQR1XS
NCI-H1048 NGTPVFlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M2\BcWlEPTB;MD61NFk2OyEQvF2= MUPTRW5ITVJ?
SW1417 NITwUGNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NEjkTWZKSzVyPUCuOVU1OzhizszN NV3HfZNFW0GQR1XS
DB Ml;lS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? Ml7OTWM2OD1yLkW3NFgh|ryP NIXYcm5USU6JRWK=
MEG-01 NXXtb3p[T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MmPsTWM2OD1yLkW4N|Ih|ryP MW\TRW5ITVJ?
EW-13 NUjWNYJJT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NWLsR5FuUUN3ME2wMlU5OzRzIN88US=> NXPFblh4W0GQR1XS
LAMA-84 M3rxd2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NEjZTlBKSzVyPUCuOVkzODdizszN NXPFfWFRW0GQR1XS
J-RT3-T3-5 MoT1S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NEHJR5VKSzVyPUCuOlA5ODhizszN MlHaV2FPT0WU
MOLT-16 NXT6eXk5T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NG\KTphKSzVyPUCuOlUzPjRizszN MmPUV2FPT0WU
DU-4475 MmCzS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NFraSIJKSzVyPUCuOlU1OjdizszN MnvGV2FPT0WU
HAL-01 NVyx[oU1T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MX3JR|UxRTBwN{K1OFkh|ryP MnXkV2FPT0WU
RD M1q4WGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MVfJR|UxRTBwN{W4PVkh|ryP NYXrU3hnW0GQR1XS
OAW-28 M3nCNWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MUnJR|UxRTBwN{izO{DPxE1? MojYV2FPT0WU
HCC38 MmriS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M2\aUmlEPTB;MD64NFE6KM7:TR?= MmnXV2FPT0WU
NMC-G1 MXTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MWPJR|UxRTBwOEGxNlEh|ryP MkfPV2FPT0WU
EW-16 M{LYdWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M{\uOmlEPTB;MD64NVMzQCEQvF2= MlrFV2FPT0WU
DU-145 M4\EbGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 Ml3GTWM2OD1yLki5PVI{KM7:TR?= MWjTRW5ITVJ?
HPAF-II NHn4bWJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M4[2PGlEPTB;MD65NlYzQCEQvF2= MnfSV2FPT0WU
A427 MUfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NFn2[4hKSzVyPUCuPVMxOjJizszN NFewdZNUSU6JRWK=
PA-1 NUfxXJRxT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NF70XVJKSzVyPUCuPVU3PDJizszN NFm4WpdUSU6JRWK=
OAW-42 MX3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MWLJR|UxRTBwOU[xOFYh|ryP NGftclRUSU6JRWK=
L-428 NI[1PYRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NUTkSIJrUUN3ME2xMlAyOjVizszN NXvCUopuW0GQR1XS
COLO-824 MV\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NIDpc2xKSzVyPUGuNFE4ODhizszN M4eyVXNCVkeHUh?=
P30-OHK NXjWNYx2T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NHvsOnBKSzVyPUGuNFQ3QDhizszN M1XvOXNCVkeHUh?=
NCI-H2170 MkXVS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M1XnUGlEPTB;MT6wOlI{KM7:TR?= MYLTRW5ITVJ?
HCC2998 MoXVS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NVX3R2txUUN3ME2xMlA4OTN3IN88US=> NYrHWndGW0GQR1XS
NB14 M4HpfWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NFfyd4xKSzVyPUGuNVM4PDhizszN M17jT3NCVkeHUh?=
TGBC1TKB NYTrclhFT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NV;EOGNYUUN3ME2xMlE1OTV{IN88US=> M1K0[XNCVkeHUh?=
KP-N-YS NWm1[3RrT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NUDJWXNSUUN3ME2xMlE3OjN4IN88US=> MUjTRW5ITVJ?
CAL-120 NETlNGpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NH3vPWRKSzVyPUGuNVY1OjlizszN Mnz1V2FPT0WU
SBC-1 MXnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MWXJR|UxRTFwMUmwOVMh|ryP NYnz[oJyW0GQR1XS
C32 MmTFS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NWPQVWdIUUN3ME2xMlE6ODh6IN88US=> Ml3UV2FPT0WU
HCC2157 M{eyfWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MoPsTWM2OD1zLkG5OFk1KM7:TR?= M1jKW3NCVkeHUh?=
COLO-792 MX7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MUPJR|UxRTFwMkCwO|Eh|ryP M4j0NXNCVkeHUh?=
ES7 MmPYS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M13ae2lEPTB;MT6yO|k2OSEQvF2= MXvTRW5ITVJ?
HEL MV3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MXPJR|UxRTFwM{GwNlkh|ryP NXr0VWtDW0GQR1XS
ES4 NF61TnBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MlXITWM2OD1zLkO0PVk5KM7:TR?= NHXQNJVUSU6JRWK=
NCI-SNU-1 MlzhS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NED4THBKSzVyPUGuN|Y2PTVizszN MkDwV2FPT0WU
MDA-MB-415 MnTzS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MXHJR|UxRTFwM{i4OUDPxE1? M4rKZnNCVkeHUh?=
NCI-H2342 MV3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NEKxVpVKSzVyPUGuOFAzPjlizszN NI[3T3VUSU6JRWK=
NB69 M2\Lb2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M1WyXmlEPTB;MT60OlI4OSEQvF2= M4nT[nNCVkeHUh?=
D-247MG MVPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M13GbWlEPTB;MT61NVEzOiEQvF2= NV3hRXkxW0GQR1XS
SCC-4 MXnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NF65fZhKSzVyPUGuOVk5QDdizszN M{TyUHNCVkeHUh?=
HuH-7 M1zoeWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MX3JR|UxRTFwNkeyPVMh|ryP MkTLV2FPT0WU
A388 MWTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? Mn3NTWM2OD1zLk[4O|I1KM7:TR?= Mn:yV2FPT0WU
Calu-3 MlfmS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M{\2OWlEPTB;MT63NFY6PyEQvF2= NVnxV5JyW0GQR1XS
NCI-H1648 M4DlVGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NXm4OWk{UUN3ME2xMlcyPDF6IN88US=> NVHDe5ZmW0GQR1XS
NCI-H2052 Mkj2S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MlXTTWM2OD1zLkeyNlAyKM7:TR?= MWTTRW5ITVJ?
Ramos-2G6-4C10 NIjTVIJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NE[zOWhKSzVyPUGuO|M3PTZizszN MX3TRW5ITVJ?
DEL NIHTNopIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NGL1dWlKSzVyPUGuO|Q3QTJizszN MWrTRW5ITVJ?
SNU-423 MVjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MXnJR|UxRTFwN{ixOVch|ryP M4LJVXNCVkeHUh?=
COR-L23 M4rPdGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M3LpcmlEPTB;MT63PVg4PCEQvF2= M3fTV3NCVkeHUh?=
OMC-1 MmS2S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NF\5WZNKSzVyPUGuPFYxOTZizszN MlvXV2FPT0WU
EW-11 NIfDcZlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M2DjemlEPTB;MT65OVY2PyEQvF2= M1\1eXNCVkeHUh?=
HSC-3 NFHTd4hIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MUPJR|UxRTFwOU[zOlUh|ryP MmO2V2FPT0WU
MLMA M3q5NGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M3vVVGlEPTB;MT65OlY4PyEQvF2= M4rLUHNCVkeHUh?=
RCM-1 MULHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MljhTWM2OD1{LkCwN|k6KM7:TR?= NVTVe28{W0GQR1XS
MFE-280 M33mN2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NWL4NFBuUUN3ME2yMlAzQDR6IN88US=> MVzTRW5ITVJ?
ES8 MVXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MkC2TWM2OD1{LkK1OFcyKM7:TR?= MX\TRW5ITVJ?
TE-11 MYDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NHjTOIxKSzVyPUKuNlk1PzNizszN M4rOb3NCVkeHUh?=
HuO-3N1 MXXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MXvJR|UxRTJwNEi3PEDPxE1? NEnhemxUSU6JRWK=
MHH-NB-11 NFPXenBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NVXE[HY4UUN3ME2yMlUyOTV6IN88US=> NH71bmZUSU6JRWK=
TGBC11TKB MkTOS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NWO4VnZMUUN3ME2yMlU4PjhzIN88US=> NV7Wd4RkW0GQR1XS
HOP-92 MWDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MnLhTWM2OD1{LkW4O|Q{KM7:TR?= NXvHdmhpW0GQR1XS
IGR-1 M2jtV2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MXjJR|UxRTJwNkKwN|Uh|ryP NE[5RWVUSU6JRWK=
GOTO NETi[oNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NH3VN3VKSzVyPUKuOlU{PzdizszN MXzTRW5ITVJ?
NCI-H1650 NYnxRppYT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NIDQb|hKSzVyPUKuO|IzOTVizszN MXTTRW5ITVJ?
NCI-H1581 NVPNOm02T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NES5bVJKSzVyPUKuO|k3QDFizszN M4fDeHNCVkeHUh?=
NCI-H2405 NH;W[GhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MWrJR|UxRTJwOEK3PFIh|ryP MlPoV2FPT0WU
U-118-MG NYPZb4t7T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NE\CUXBKSzVyPUKuPVY1QTFizszN NVroeFJ[W0GQR1XS
DoTc2-4510 NGLJ[lZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MXTJR|UxRTNwMEG0NVch|ryP MlvvV2FPT0WU
NCI-H596 NWfCb4VsT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M2K4bmlEPTB;Mz6wOFk6PyEQvF2= MoDYV2FPT0WU
MPP-89 MWfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MoWwTWM2OD1|LkC1OlY3KM7:TR?= Moe2V2FPT0WU
GCIY NVjKWoRRT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NVnBPYw2UUN3ME2zMlIxPDlzIN88US=> MUnTRW5ITVJ?
SW626 NXuwNWlVT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MnfSTWM2OD1|LkK0OVQ{KM7:TR?= MlXDV2FPT0WU
OCI-AML2 NIKzV5RIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NXfPTphOUUN3ME2zMlMyOjd{IN88US=> NFLSUnpUSU6JRWK=
NBsusSR MX3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NVv3OHVIUUN3ME2zMlM1QTN6IN88US=> NIn3OnRUSU6JRWK=
AN3-CA NFTkO5BIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MoTWTWM2OD1|LkS0NlM5KM7:TR?= NV;w[GNbW0GQR1XS
EFM-19 MYTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M{DEOWlEPTB;Mz60PFM{QSEQvF2= MXPTRW5ITVJ?
RVH-421 MYrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MYLJR|UxRTNwNU[4O|ch|ryP MWHTRW5ITVJ?
5637 Ml;OS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NWHzeGN2UUN3ME2zMlYyOTB|IN88US=> MmjxV2FPT0WU
PANC-08-13 MXfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M4TVUmlEPTB;Mz62N|Q4OiEQvF2= M2DEU3NCVkeHUh?=
H9 MW\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MkDETWM2OD1|Lk[3NVQ1KM7:TR?= M2rsfHNCVkeHUh?=
KARPAS-299 MonKS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MlfuTWM2OD1|Lk[3N|YyKM7:TR?= NV3oT48{W0GQR1XS
TE-5 NWfITnMzT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MUDJR|UxRTNwN{C3NFkh|ryP MYjTRW5ITVJ?
NOS-1 NY[3WnFKT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MnfQTWM2OD1|Lke5PFM1KM7:TR?= NGX6ZndUSU6JRWK=
HH NEHKZZRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MlL0TWM2OD1|LkizPFY5KM7:TR?= MXXTRW5ITVJ?
769-P NV7Le3piT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M17F[2lEPTB;Mz64PVUyKM7:TR?= NHLEZ4pUSU6JRWK=
CHP-212 MXrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NYO2TGJPUUN3ME2zMlkzPTR7IN88US=> NHy3UWFUSU6JRWK=
NCI-H82 MVrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M4XscmlEPTB;Mz65OVk{PiEQvF2= NEjTWm5USU6JRWK=
Mo-T NH7CW|JIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MmjOTWM2OD12LkC0N|EzKM7:TR?= MmrpV2FPT0WU
BB65-RCC MnH1S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NE\3NnVKSzVyPUSuNFQ{QTlizszN NUiyOXVbW0GQR1XS
SW1990 Mn7rS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MoqxTWM2OD12LkC1PVA5KM7:TR?= Mn\IV2FPT0WU
LK-2 M{T2OWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NX3aZZpYUUN3ME20MlEyOjl|IN88US=> M{HjdXNCVkeHUh?=
ES5 Mk[2S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M3rvXWlEPTB;ND6xN|k5PSEQvF2= NYTVWmVMW0GQR1XS
JVM-3 MYPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MlfwTWM2OD12LkG4NlIzKM7:TR?= MXvTRW5ITVJ?
RPMI-7951 M2excWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NVy0U21QUUN3ME20MlIzPDF|IN88US=> M1nR[nNCVkeHUh?=
Calu-6 NHvpS2VIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M1nQN2lEPTB;ND6yO|g5OSEQvF2= MXHTRW5ITVJ?
LC-2-ad NX\MVI1nT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MlPETWM2OD12LkK5OVY5KM7:TR?= NGG5enVUSU6JRWK=
SW954 MYPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NVqyVo54UUN3ME20MlI6PjZizszN NUTjV2w1W0GQR1XS
H-EMC-SS NVHUVmU4T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NFjyTFdKSzVyPUSuN|E5OzFizszN NHrqcmhUSU6JRWK=
ES3 NFn6WmRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NGKwbI1KSzVyPUSuN|U1PDFizszN NVK1PJI{W0GQR1XS
no-11 MVPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NE\3WHhKSzVyPUSuN|U2PTRizszN MmrtV2FPT0WU
LAN-6 NETFR2pIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MXHJR|UxRTRwNEWxPFkh|ryP NG[3N2pUSU6JRWK=
FTC-133 NFXVTIJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MYPJR|UxRTRwNUO5OUDPxE1? M{\sfXNCVkeHUh?=
8505C MXzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NUO5NJFwUUN3ME20MlU1OjNizszN MnrsV2FPT0WU
SW620 MYfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? Mn6zTWM2OD12LkW3NFU4KM7:TR?= NGL4c|VUSU6JRWK=
BCPAP NVrmfFVsT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NVLwZnF1UUN3ME20MlY{PDhzIN88US=> NYPjfohWW0GQR1XS
SK-LU-1 MUTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NEjlXIdKSzVyPUSuOlYxQDlizszN M4\jSnNCVkeHUh?=
NCI-H1623 NXXkbVl4T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NV;oOW5KUUN3ME20MlcxOjJ6IN88US=> M1juTXNCVkeHUh?=
C2BBe1 NFTrflVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NWjDfmFqUUN3ME20Mlc1ODB6IN88US=> MWjTRW5ITVJ?
GP5d M4f3eGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MV7JR|UxRTRwN{izPFgh|ryP NF24XHFUSU6JRWK=
NB6 Ml63S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MWPJR|UxRTRwOE[yNFQh|ryP M1P1OHNCVkeHUh?=
MDA-MB-157 MmrGS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NFTHOpJKSzVyPUSuPFg4PiEQvF2= NXL2UplyW0GQR1XS
UMC-11 NGHRVoVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MnPuTWM2OD12Lki4PVY1KM7:TR?= MULTRW5ITVJ?
HCC1419 NHT0c41Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MX7JR|UxRTRwOUCwOlMh|ryP NEHXSXRUSU6JRWK=
NCI-H2029 NGrpTXRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MWfJR|UxRTRwOUSxPFUh|ryP NXzzb29UW0GQR1XS
LXF-289 MUfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M3;vdWlEPTB;NT6wN|cyQSEQvF2= M4\lfHNCVkeHUh?=
KINGS-1 MlTJS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MYDJR|UxRTVwMEe3OFQh|ryP M1[wNnNCVkeHUh?=
HD-MY-Z Mkf4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NFOwNVJKSzVyPUWuNlM6PjlizszN NVq1OpBjW0GQR1XS
ESS-1 MmXwS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NYnLZmFGUUN3ME21MlI2PTl5IN88US=> NEfxd2pUSU6JRWK=
GI-1 NGiyNJhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M2W1TmlEPTB;NT6yO|kzPiEQvF2= MnrSV2FPT0WU
RPMI-2650 M1HseGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MnuwTWM2OD13LkO2NVYh|ryP MmG5V2FPT0WU
IA-LM MnjaS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M4HY[WlEPTB;NT6zPVg4OSEQvF2= MoK3V2FPT0WU
KP-4 MmTKS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NWXzUWFNUUN3ME21MlQ3OzN2IN88US=> M{nzVXNCVkeHUh?=
G-402 NH7vRpRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NWTTcXNqUUN3ME21MlUyQDZ3IN88US=> MoDxV2FPT0WU
OS-RC-2 NEfaOZNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MXfJR|UxRTVwNUK2NFQh|ryP MYLTRW5ITVJ?
NCI-H1155 M1z1Umdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 Ml\ITWM2OD13LkW0PVU2KM7:TR?= MUjTRW5ITVJ?
OE19 MnnUS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? Mm\xTWM2OD13Lk[4OlI1KM7:TR?= NWLONYh5W0GQR1XS
U-2-OS M3n5emdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M{WycmlEPTB;NT64PVAyOyEQvF2= M2P6OXNCVkeHUh?=
SCC-15 NX;PS4F4T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NYfVT4l3UUN3ME21Mlk{PjZ{IN88US=> NYniSG1jW0GQR1XS
NCI-H630 NFHHXJVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MkDxTWM2OD13Lkm5OFA1KM7:TR?= M3\nTnNCVkeHUh?=
PFSK-1 MY\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NUTleVN[UUN3ME22MlA2OjV7IN88US=> M1Oz[XNCVkeHUh?=
NCI-H1770 NHvyZYtIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MYPJR|UxRTZwMkC4O|Qh|ryP M4DJWXNCVkeHUh?=
SK-MEL-3 M2CxbGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NIXtblNKSzVyPU[uOFI6OTVizszN M4PLRXNCVkeHUh?=
LB1047-RCC NGTORotIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M1ryRmlEPTB;Nj60O|YzPSEQvF2= M2XsUXNCVkeHUh?=
NCI-H446 NX\ZV495T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NXjQe4kxUUN3ME22MlYzQTJ3IN88US=> Ml6wV2FPT0WU
SW780 NHLuV3ZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NHywWVhKSzVyPU[uO|AyQDVizszN MkXLV2FPT0WU
NEC8 M37MUmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M3zNSWlEPTB;Nj63OlY{KM7:TR?= NVK2dYMxW0GQR1XS
NOMO-1 NGrab2NIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NYnSPI9GUUN3ME22Mlc5OTFzIN88US=> NIS4U5pUSU6JRWK=
COLO-668 MX\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M2n2RWlEPTB;Nj64OFM5PyEQvF2= MV3TRW5ITVJ?
MC116 M17yd2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MWDJR|UxRTZwOUO4PVch|ryP M{PqPHNCVkeHUh?=
HCC1937 MV\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NVvieHJ6UUN3ME22Mlk6OjVzIN88US=> Mn;OV2FPT0WU
NCI-N87 MWTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MU\JR|UxRTdwMUmyPVMh|ryP M2PjSnNCVkeHUh?=
COLO-320-HSR MmLRS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MY\JR|UxRTdwMkK3N|gh|ryP MVjTRW5ITVJ?
HCC1806 NVXm[HM{T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NET0[lJKSzVyPUeuNlYxPDRizszN MkWwV2FPT0WU
OVCAR-3 Mn\ES5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NELHSpVKSzVyPUeuN|MxOzhizszN NVLEcIVPW0GQR1XS
NUGC-3 M2j3T2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M33uNmlEPTB;Nz6zPVY6PCEQvF2= MVTTRW5ITVJ?
SW1783 NVPocGdKT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NXL3V3BuUUN3ME23MlQ{OTd3IN88US=> NXzvW3NJW0GQR1XS
GCT NIrRcplIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M1vSUGlEPTB;Nz61OlkxPiEQvF2= Mk\kV2FPT0WU
NCI-H2126 NVXNeJp4T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NX3GZXo3UUN3ME23Mlc{PjJ3IN88US=> M{\NRnNCVkeHUh?=
MEL-HO NIrrUXJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MoqzTWM2OD15Lke3NFU1KM7:TR?= NIOzcIRUSU6JRWK=
CAPAN-1 M2e0cGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NYXsWIlDUUN3ME23Mlc4OzV5IN88US=> M3X6SHNCVkeHUh?=
SW756 NWmzNZR4T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MmTTTWM2OD15Lke4N|M{KM7:TR?= MnHQV2FPT0WU
SKG-IIIa M3XYUWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MXLJR|UxRTdwOEG4PVIh|ryP NF7obolUSU6JRWK=
HCE-T MX\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M4e5ZmlEPTB;Nz64O|c5OyEQvF2= NInoUmRUSU6JRWK=
Ca-Ski Ml;YS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M4T1dmlEPTB;Nz65PVM5OyEQvF2= MkO1V2FPT0WU
COLO-684 NFe0b2FIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NU\QeWY5UUN3ME24MlAyQDF6IN88US=> MojLV2FPT0WU
KYSE-70 MlXPS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NFrycolKSzVyPUiuNFc4OjlizszN NUXob3F4W0GQR1XS
TI-73 M{LKS2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NX\KUmRSUUN3ME24MlI2QDVzIN88US=> MVXTRW5ITVJ?
BT-20 MWfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MW\JR|UxRThwMk[wOVIh|ryP MULTRW5ITVJ?
MHH-ES-1 NXy4Z3M{T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MXrJR|UxRThwNUG4N|Qh|ryP MXvTRW5ITVJ?
TE-12 MnHLS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MkLLTWM2OD16LkW5PVMyKM7:TR?= MVnTRW5ITVJ?
YH-13 MoXrS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NWjxTIVUUUN3ME24MlYyODB6IN88US=> M{jCRXNCVkeHUh?=
SF126 NVfmdZptT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MnPlTWM2OD16LkizPFY2KM7:TR?= Mke1V2FPT0WU
J82 NYHZepBOT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MWLJR|UxRThwOUCwN|gh|ryP NIjORYlUSU6JRWK=
RCC10RGB MUjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M1HLZmlEPTB;OD65PVU3OSEQvF2= MWfTRW5ITVJ?
SK-UT-1 MoLpS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NFH3XW1KSzVyPUmuNFQ6PDVizszN MnnlV2FPT0WU
LB2241-RCC NWGxfJF5T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NHHnOpFKSzVyPUmuNVkyOzdizszN MV;TRW5ITVJ?
LB996-RCC NX3zNVk2T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MlztTWM2OD17LkG5PFkh|ryP M4rMUnNCVkeHUh?=
EPLC-272H MXHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MUTJR|UxRTlwM{e2OVch|ryP NXLl[2NQW0GQR1XS
CTV-1 NVTFPFg{T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NHzLVmNKSzVyPUmuOVY2OzJizszN Mn:yV2FPT0WU
HSC-2 MoLBS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MVfJR|UxRTlwNUe1OUDPxE1? MYjTRW5ITVJ?
SK-MEL-28 NVfzNHY5T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NYO3PWNNUUN3ME25MlYyQDl|IN88US=> NYW0[XY4W0GQR1XS
MMAC-SF M1i1Wmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NV7Re5RkUUN3ME25MlY5PzVizszN MVTTRW5ITVJ?
CP50-MEL-B NH61RYpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= Mnm2TWM2OD17Lke1O|gzKM7:TR?= MnXXV2FPT0WU
HT-1080 MoDBS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NWjrW4s1UUN3ME25Mlc4PzN7IN88US=> MU\TRW5ITVJ?
HEC-1 NFv3e3hIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NXHGWFd[UUN3ME2xNE4{OzV{IN88US=> MVPTRW5ITVJ?
AGS MVfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NGr1d4VKSzVyPUGwMlM4PCEQvF2= NH74bJZUSU6JRWK=
GAMG NEGwS2VIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NHXoRZFKSzVyPUGwMlUyPjJizszN M{TGSXNCVkeHUh?=
SW48 M4nzVWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MnfGTWM2OD1zMD61NVg6KM7:TR?= M4TtVXNCVkeHUh?=
U031 NFHKd2RIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NHXnVnhKSzVyPUGwMlU6ODhizszN NYnGN3dmW0GQR1XS
OVCAR-5 NV34eXNQT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MnLTTWM2OD1zMD62OFI6KM7:TR?= MlHWV2FPT0WU
SF295 M{jY[mdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NWDJWGtSUUN3ME2xNE43PzB2IN88US=> MXLTRW5ITVJ?
BHT-101 MlLiS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MUTJR|UxRTFyLkexO|ch|ryP MnezV2FPT0WU
VMRC-RCZ M1jlV2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NYT2WpB[UUN3ME2xNU4{OjBzIN88US=> MkHRV2FPT0WU
ACHN M2DjOGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M2n0bWlEPTB;MUGuOFIyOSEQvF2= M2HlfHNCVkeHUh?=
NCI-H526 NH7CPY1Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NGTCfW1KSzVyPUGxMlUxPDNizszN M3TzWHNCVkeHUh?=
MN-60 MWjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NW\CS4Z1UUN3ME2xNU42OzlizszN MnfOV2FPT0WU
NCI-H2291 NFnXWoZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MUHJR|UxRTFzLkW0OlYh|ryP M4[1Z3NCVkeHUh?=
SCC-25 MWnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NXrHe3BrUUN3ME2xNU44PTV4IN88US=> M3fPSXNCVkeHUh?=
SK-MEL-2 MnLYS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NUXCSoV{UUN3ME2xNU44PjN5IN88US=> MXXTRW5ITVJ?
SN12C MnPTS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M{nWZmlEPTB;MUGuPVM2PSEQvF2= MULTRW5ITVJ?
NCI-H69 NF\HZWJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MXnJR|UxRTF{LkSyN|Qh|ryP NGDvPFNUSU6JRWK=
ME-180 MWfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M4nHWWlEPTB;MUKuO|A2PCEQvF2= NUHXSItFW0GQR1XS
MC-IXC NEfEc5ZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MVPJR|UxRTF{Lke1NVgh|ryP NILkTXFUSU6JRWK=
NCI-H2347 MYXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NVzYUVd3UUN3ME2xNk44PjF2IN88US=> NHnsTVJUSU6JRWK=
M059J NXntOlZRT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M2XEeWlEPTB;MUKuO|czPyEQvF2= M2nzWnNCVkeHUh?=
A2058 NYf0d49tT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M{\NeWlEPTB;MUKuPFY5OSEQvF2= MUnTRW5ITVJ?
VA-ES-BJ M3HkWmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M3O4UGlEPTB;MUKuPFc5PSEQvF2= MnPhV2FPT0WU
Ca9-22 M1HaVWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MUfJR|UxRTF{Lkm0OVEh|ryP MV7TRW5ITVJ?
KNS-42 NG\2VHBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NIDnWWNKSzVyPUGyMlk6QDRizszN NFL2VXNUSU6JRWK=
LoVo MkTxS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MXnJR|UxRTF|LkKzNVMh|ryP NYTWWZBSW0GQR1XS
AM-38 M13FXmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M4HEU2lEPTB;MUOuNlU3PiEQvF2= M{XLVXNCVkeHUh?=
NB5 Ml:4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MW\JR|UxRTF|LkO3OVIh|ryP NV71NFRNW0GQR1XS
L-363 NUTUUZpxT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NHLkXFZKSzVyPUGzMlQxOzNizszN MoDjV2FPT0WU
SK-MEL-30 MYTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M3fTTmlEPTB;MUSuNFY1PSEQvF2= NIr6RYVUSU6JRWK=
NCI-H1563 NYe4eXZ3T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M4fnRWlEPTB;MUSuOlA{QSEQvF2= M4DnenNCVkeHUh?=
NCI-H2228 M2nMVGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NFXRSZdKSzVyPUG0MlYxPzdizszN NVLIfohKW0GQR1XS
MFM-223 NFflNIxIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MlnsTWM2OD1zNT6xPFE{KM7:TR?= M3zV[nNCVkeHUh?=
LB831-BLC MmS1S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MnnmTWM2OD1zNT6yO|Y4KM7:TR?= NHLZUGlUSU6JRWK=
SW872 M2nMOmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M1TEOGlEPTB;MUWuN|A5PiEQvF2= M4XtenNCVkeHUh?=
NCI-H522 MWjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NVrKZ|RYUUN3ME2xOU4{OzB4IN88US=> NWHzSZhCW0GQR1XS
EW-1 NILXbnpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MlK1TWM2OD1zNT61OFYzKM7:TR?= M2n1SnNCVkeHUh?=
HN M1zQc2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 Mle3TWM2OD1zNT61PVQzKM7:TR?= MYHTRW5ITVJ?
SW837 MkjsS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M13m[mlEPTB;MUWuO|g1PyEQvF2= NYWwVYZHW0GQR1XS
SCC-9 MnTBS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NHTOUGhKSzVyPUG1MlgyOTRizszN M{XIdHNCVkeHUh?=
MKN7 M1TnUmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M1[4[mlEPTB;MUWuPVc{OiEQvF2= MXHTRW5ITVJ?
KYSE-410 MX7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NGO1SphKSzVyPUG2MlU6OSEQvF2= NVrXfplNW0GQR1XS
SK-N-DZ NITpTIFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NHPUepRKSzVyPUG2MlYyOTZizszN MmSyV2FPT0WU
COR-L105 MnznS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? Mnf6TWM2OD1zNj62OVI5KM7:TR?= M3npPXNCVkeHUh?=
LB2518-MEL MXrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M2jXZ2lEPTB;MU[uPFM5QSEQvF2= NX35e4hlW0GQR1XS
OVCAR-4 Mkj3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MYDJR|UxRTF4Lki4OlIh|ryP NHHrfoxUSU6JRWK=
TK10 MoP3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MUjJR|UxRTF4Lkm0O|Mh|ryP MXzTRW5ITVJ?
KNS-62 NEfYVY5Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NV[wTGd[UUN3ME2xOk46Pzd5IN88US=> NUDnclRWW0GQR1XS
RPMI-8866 NXSxcoplT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MUPJR|UxRTF5LkG3N|Ih|ryP NXrjSZBuW0GQR1XS
HuP-T4 NV3mNZJRT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NYOyeGJ[UUN3ME2xO{4zPDl3IN88US=> MWfTRW5ITVJ?
CGTH-W-1 NIHhR4ZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M4fyfWlEPTB;MUeuOVIyQSEQvF2= M3PBOnNCVkeHUh?=
T-24 MnTUS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NHi4RZFKSzVyPUG3MlU{PDdizszN MVvTRW5ITVJ?
HT-3 NV7zdYpDT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MYLJR|UxRTF5LkW5NVQh|ryP MlTmV2FPT0WU
KS-1 M{PjR2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NFKwc5hKSzVyPUG3MlY4OyEQvF2= MlvVV2FPT0WU
NCI-H1792 NEXQV5BIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M1;hcGlEPTB;MUeuO|k5KM7:TR?= M2DWfHNCVkeHUh?=
ABC-1 MVfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MUfJR|UxRTF5LkixOFEh|ryP NGLPOZhUSU6JRWK=
BPH-1 NVjXSIpXT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M3HX[mlEPTB;MUiuNVY5PSEQvF2= MonKV2FPT0WU
A431 M{PnZ2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MV;JR|UxRTF6LkSxNlch|ryP Mme3V2FPT0WU
T98G NX\vWIRuT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M{S1UWlEPTB;MUiuOVE2PyEQvF2= NHj6NotUSU6JRWK=
BHY NYP4[3ZVT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MUTJR|UxRTF6Lki2PUDPxE1? MV;TRW5ITVJ?
Capan-2 MmnXS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NYjncG5vUUN3ME2xPE46ODd6IN88US=> MYLTRW5ITVJ?
MDA-MB-175-VII M3XUdGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NXLPUYtIUUN3ME2xPE46OjB7IN88US=> M4iwPHNCVkeHUh?=
CAL-27 MV;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MmS0TWM2OD1zOT6wOFg4KM7:TR?= Mmn5V2FPT0WU
AsPC-1 NH;lc2lIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= Mo\5TWM2OD1zOT64OlU4KM7:TR?= M1nKOXNCVkeHUh?=
KU812 NGTtV5VIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NYrGV|hzUUN3ME2xPU46PTd|IN88US=> M{\hNnNCVkeHUh?=
NCI-H441 Mn\qS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MWXJR|UxRTJyLkCwNUDPxE1? MnLFV2FPT0WU
Mewo NX\LdpNCT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NEHEO4JKSzVyPUKwMlEzQDhizszN NIXGbIlUSU6JRWK=
SK-MEL-24 NXLF[oNPT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M17HeWlEPTB;MkCuNVQ4PyEQvF2= NVH2XVdOW0GQR1XS
NCI-H727 M2rEeWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NWezSYxXUUN3ME2yNE4zPzB2IN88US=> NVewZ3pJW0GQR1XS
EKVX MlXuS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NUG2RnlMUUN3ME2yNE43ODZizszN M2\yTHNCVkeHUh?=
RT-112 NVjQdldFT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NVTxZ|N3UUN3ME2yNE43OTJ{IN88US=> MXnTRW5ITVJ?
CAMA-1 NVzwXGFuT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NWPWdFJDUUN3ME2yNE46QDB|IN88US=> M2TPNnNCVkeHUh?=
SW900 NXy0elY4T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MVXJR|UxRTJzLkCxOFkh|ryP NF3XR|RUSU6JRWK=
NCI-H23 MUHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M1vscWlEPTB;MkGuNVI4PyEQvF2= MXjTRW5ITVJ?
SK-PN-DW NXLGXFQ5T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NEHwTG1KSzVyPUKxMlE3PDlizszN NVH3NXdqW0GQR1XS
BB30-HNC M2fHV2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MnXLTWM2OD1{MT6yO|Q2KM7:TR?= MULTRW5ITVJ?
VM-CUB-1 M2PUVmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M2LKRmlEPTB;MkGuN|U{PiEQvF2= M3XNOnNCVkeHUh?=
IST-MEL1 M{XkXGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MWLJR|UxRTJzLkO2PVIh|ryP M3P2RnNCVkeHUh?=
CTB-1 MkDhS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NYW3UXRzUUN3ME2yNU41PzV3IN88US=> NUT4fVRPW0GQR1XS
LCLC-103H MlfoS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NULCVZZIUUN3ME2yNk4yPTh{IN88US=> NUfTRoR{W0GQR1XS
PANC-03-27 NXu0S4J6T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NHLzTVFKSzVyPUKyMlUyPjlizszN NWHLPIN4W0GQR1XS
HTC-C3 NV:3dIVCT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M2fSVmlEPTB;MkKuOVU2PSEQvF2= M3z6WHNCVkeHUh?=
TE-8 MYrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NVfjV2NVUUN3ME2yN{4zPTZ3IN88US=> NFv3Z5hUSU6JRWK=
NCI-H292 MYjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MU\JR|UxRTJ3LkO1N|Yh|ryP M2PvZXNCVkeHUh?=
COLO-680N M3jaR2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M1W3VGlEPTB;MkWuOlMzQSEQvF2= M2ezNHNCVkeHUh?=
KYSE-520 NWHQeHV2T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MmLGTWM2OD1{NT62OFQh|ryP MoDLV2FPT0WU
NB10 M3G4OGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NETRbVFKSzVyPUK2MlMyOTdizszN M{HI[3NCVkeHUh?=
NCI-H661 M2PheWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M{O2TmlEPTB;Mk[uOFcyOyEQvF2= NHqz[ZRUSU6JRWK=
GMS-10 MVLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M13GWmlEPTB;Mk[uPFY{QCEQvF2= MX;TRW5ITVJ?
NCI-H2122 MWjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M1q1[GlEPTB;Mk[uPVk6QCEQvF2= MlL6V2FPT0WU
OVCAR-8 M1fVdmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M3:0NWlEPTB;MkeuNFY{QCEQvF2= MYDTRW5ITVJ?
DJM-1 NGPnVWJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M3LCd2lEPTB;MkeuNVQ2PCEQvF2= NXW3UVM5W0GQR1XS
UACC-893 NV7IeIQyT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MnmyTWM2OD1{Nz65PFc5KM7:TR?= MX\TRW5ITVJ?
C8166 Ml:5S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M374PWlEPTB;MkiuOlk{QCEQvF2= NWXWOmx3W0GQR1XS
NCI-H1693 NHjhUYVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MoXZTWM2OD1{OD62PVc2KM7:TR?= NVi1dpd3W0GQR1XS
TYK-nu NEC0W2ZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M3\JT2lEPTB;M{CuNFM1PSEQvF2= NYfqOXFrW0GQR1XS
SW1710 MmPlS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MV3JR|UxRTNyLkGyOkDPxE1? MXXTRW5ITVJ?
A375 M2nJeGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M2HjfGlEPTB;M{CuN|I1OyEQvF2= NWGwNWxEW0GQR1XS
HMV-II NYDFTZpUT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M1HyZmlEPTB;M{GuN|U6OiEQvF2= MVXTRW5ITVJ?
NCI-H2087 MXfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? Mkn1TWM2OD1|MT62N|UzKM7:TR?= MXzTRW5ITVJ?
CAL-54 MY\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MkPOTWM2OD1|MT63NlQyKM7:TR?= M2TpRnNCVkeHUh?=
HCC70 MmLIS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MXXJR|UxRTN{LkGzPFch|ryP Mn7JV2FPT0WU
ES1 M4LN[2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 Mkn0TWM2OD1|Mj6zNFYzKM7:TR?= MXrTRW5ITVJ?
NCI-H1355 MUHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MlrUTWM2OD1|Mz6yNFQh|ryP NW\HeJRVW0GQR1XS
CFPAC-1 MnjFS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MorPTWM2OD1|Mz6yN|MzKM7:TR?= NUDSc|l1W0GQR1XS
MKN28 M2nnU2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NXrYWG9JUUN3ME2zN{4{QDB7IN88US=> MVrTRW5ITVJ?
HDLM-2 NHvjeFBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MVjJR|UxRTN|Lk[5N|Eh|ryP MUXTRW5ITVJ?
PANC-10-05 NWTocIljT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NFnJTJBKSzVyPUO0MlExOTRizszN M4juPHNCVkeHUh?=
SAS NF74XVRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NUXlW4ZIUUN3ME2zOE41PTZ3IN88US=> NWrZW4dOW0GQR1XS
HCC1395 MkHkS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NH\2RWFKSzVyPUO0MlcyQDZizszN NUW4NJpTW0GQR1XS
8305C M3\Memdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MX3JR|UxRTN3Lki0NVUh|ryP M1nEeHNCVkeHUh?=
KM12 MmmyS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NEnyOHJKSzVyPUO2Mlc2PDdizszN MkHKV2FPT0WU
SW1116 Mm\wS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M3XoeWlEPTB;M{euOVk6OiEQvF2= MYHTRW5ITVJ?
SK-MEL-1 MoLFS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M4rPRWlEPTB;M{iuN|M5QSEQvF2= NVjhR|k4W0GQR1XS
HCC2218 MUTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MnzNTWM2OD1|OD62OVE6KM7:TR?= M1POfXNCVkeHUh?=
T84 M37sR2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NFuxO2NKSzVyPUO4Mlc1ODlizszN MUfTRW5ITVJ?
ETK-1 NIrRbnpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NEDrUFFKSzVyPUO5MlAzOiEQvF2= MYXTRW5ITVJ?
COLO-800 NH3JeohIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MlPlTWM2OD1|OT6zPFY5KM7:TR?= MojWV2FPT0WU
CAL-12T MXzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NFfNS5NKSzVyPUO5MlUzQDFizszN MkS0V2FPT0WU
ACN NVe4T2hpT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NX7VTYV3UUN3ME20NE41QTFzIN88US=> MWDTRW5ITVJ?
SJSA-1 MYTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M{DnT2lEPTB;NEGuNVU6PiEQvF2= NY\GbIdNW0GQR1XS
PSN1 MVzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MXTJR|UxRTRzLkG3OFkh|ryP NXjy[GF6W0GQR1XS
D-566MG Ml\sS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M4rNOmlEPTB;NEGuNlA5PiEQvF2= M4r2cnNCVkeHUh?=
EGI-1 MkOwS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MoqzTWM2OD12Mj60Nlgh|ryP Mme1V2FPT0WU
A204 MmXmS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MlXMTWM2OD12Mj62N|g5KM7:TR?= M{DaSXNCVkeHUh?=
Saos-2 MlG3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NH:zUGJKSzVyPUSyMlg{PjlizszN NF7FNmpUSU6JRWK=
SNU-C2B NFTUNG9Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NWHEUIRmUUN3ME20N{43QDd6IN88US=> MmjDV2FPT0WU
HLE NWjSe5NyT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= Ml7VTWM2OD12ND6wPFU3KM7:TR?= M4\o[3NCVkeHUh?=
SW1463 NIj2NI5Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M2fzTWlEPTB;NESuPVk4OSEQvF2= NHf5Sm5USU6JRWK=
DSH1 M2TLVGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M4npeWlEPTB;NEWuNFA{OyEQvF2= NGS1[5dUSU6JRWK=
MCF7 NXLreY1vT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MlnuTWM2OD12NT61NFUyKM7:TR?= NWmycm9bW0GQR1XS
K5 MVzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NGjT[49KSzVyPUS1Mlk1ODVizszN MV;TRW5ITVJ?
NCI-H358 NWXnelF6T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MnrDTWM2OD12Nz6yNVUh|ryP NFX5SJhUSU6JRWK=
NCI-H2030 MnTRS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NUfCcJNnUUN3ME20O{4zOzd2IN88US=> MYnTRW5ITVJ?
SW948 MUDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MW\JR|UxRTR5LkS2OEDPxE1? M3fqTHNCVkeHUh?=
BALL-1 MmrYS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NHf1dmpKSzVyPUS3MlYyPjhizszN NHzNXXNUSU6JRWK=
TE-9 NELLdHpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= Mo\6TWM2OD12Nz65OVgyKM7:TR?= NYjwNIJzW0GQR1XS
SK-N-FI M3fFNWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NEHhRXdKSzVyPUS4MlA{PThizszN M2TQN3NCVkeHUh?=
KALS-1 NV7wcIRYT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MYPJR|UxRTR6LkGyPFkh|ryP NGj2cJRUSU6JRWK=
HO-1-N-1 MnjxS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NWPhcnBqUUN3ME20PE44PDR3IN88US=> MmHTV2FPT0WU
NCI-H2452 M1\yS2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NUTUelVPUUN3ME20PU4yOTV{IN88US=> NGrBVGxUSU6JRWK=
OC-314 NEfiW3VIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MnLNTWM2OD12OT62PFM1KM7:TR?= NU\pV|ZRW0GQR1XS

... Click to View More Cell Line Experimental Data

In vivo When ABT-263 is administered at 100 mg/kg/day in the H345 xenograft model, significant antitumor efficacy is observed with 80% TGI and 20% of treated tumors indicating at least a 50% reduction in tumor volume. [2] Oral administration of ABT-263 alone causes complete tumor regressions in xenograft models of small-cell lung cancer and acute lymphoblastic leukemia. In xenograft models of aggressive B-cell lymphoma and multiple myeloma where ABT-263 displays modest or no single agent activity, it significantly enhances the efficacy of clinically relevant therapeutic regimens. [2]

Protocol

Kinase Assay:

[1]

+ Expand

Affinity determination:

Binding affinities (Ki or IC50) of ABT-263 against different isoforms of Bcl-2 family are determined with competitive fluorescence polarization assays. The following peptide probe/protein pairs are used: f-bad (1 nM) and Bcl-xL (6 nM), f-Bax (1 nM) and Bcl-2 (10 nM), f-Bax (1 nM) and Bcl-w (40 nM), f-Noxa (2 nM) and Mcl-1 (40 nM), and f-Bax (1 nM) and Bcl-2-A1 (15 nM). Binding affinities for Bcl-xL are also determined using a time-resolved fluorescence resonance energy transfer assay. Bcl-xL (1 nM, His tagged) is mixed with 200 nM f-Bak, 1 nM Tb-labeled anti-His antibody, and ABT-263 at room temperature for 30 min. Fluorescence is measured on an Envision plate reader using a 340/35 nm excitation filter and 520/525 (f-Bak) and 495/510 nm (Tb-labeled anti-His antibody) emission filters.
Cell Research:

[1]

+ Expand
  • Cell lines: SCLC cell lines
  • Concentrations: 0-1 μM
  • Incubation Time: 48 hours
  • Method:

    Human tumor cell lines SCLC cell lines are maintained at 37℃ containing 5% CO2. SCLC cell lines are cultured in RPMI 1640 with 10% fetal bovine serum (FBS), 1% sodium pyruvate, 25 mM HEPES, 4.5 g/L glucose, and 1% penicillin/streptomycin. Leukemia and lymphoma cell lines are cultured in RPMI 1640 supplemented with 10% FBS and 1% penicillin/streptomycin. Cells (1-5×10 4) are treated by ABT-263 for 48 hours in 96-well culture plates in a final volume of 100 μL and cytotoxicity is assessed with the CellTiter Glo assay. In vitro cyto toxicity of ABT-263 is assayed.


    (Only for Reference)
Animal Research:

[1]

+ Expand
  • Animal Models: C.B.-17 scid-bg or C.B.-17 scid mice
  • Formulation: Formulated in 10% ethanol, 30% polyethylene glycol 400, and 60% Phosal 50 PG
  • Dosages: 100 mg/kg/d
  • Administration: Administered via p.o.
    (Only for Reference)

Solubility (25°C)

In vitro DMSO 100 mg/mL (102.6 mM)
Water Insoluble
Ethanol Insoluble
In vivo Add solvents to the product individually and in order:
5% DMSO+corn oil
7mg/mL

* Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.

Chemical Information

Molecular Weight 974.61
Formula

C47H55ClF3N5O6S3

CAS No. 923564-51-6
Storage powder
Synonyms N/A

Bio Calculators

Molarity Calculator

Molarity Calculator

Calculate the mass, volume or concentration required for a solution. The Selleck molarity calculator is based on the following equation:

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

  • Mass
    Concentration
    Volume
    Molecular Weight

*When preparing stock solutions, please always use the batch-specific molecular weight of the product found on the via label and MSDS / COA (available on product pages).

Dilution Calculator

Dilution Calculator

Calculate the dilution required to prepare a stock solution. The Selleck dilution calculator is based on the following equation:

Concentration (start) x Volume (start) = Concentration (final) x Volume (final)

This equation is commonly abbreviated as: C1V1 = C2V2 ( Input Output )

  • C1
    V1
    C2
    V2

* When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and MSDS / COA (available online).

The Serial Dilution Calculator Equation

  • Serial Dilutions

  • Computed Result

  • C1=C0/X C1: LOG(C1):
    C2=C1/X C2: LOG(C2):
    C3=C2/X C3: LOG(C3):
    C4=C3/X C4: LOG(C4):
    C5=C4/X C5: LOG(C5):
    C6=C5/X C6: LOG(C6):
    C7=C6/X C7: LOG(C7):
    C8=C7/X C8: LOG(C8):
Molecular Weight Calculator

Molecular Weight Calculator

Enter the chemical formula of a compound to calculate its molar mass and elemental composition:

Total Molecular Weight: g/mol

Tip: Chemical formula is case sensitive. C10H16N2O2 c10h16n2o2

Instructions to calculate molar mass (molecular weight) of a chemical compound:

To calculate molar mass of a chemical compound, please enter its chemical formula and click 'Calculate'.

Definitions of molecular mass, molecular weight, molar mass and molar weight:

Molecular mass (molecular weight) is the mass of one molecule of a substance and is expressed in the unified atomic mass units (u). (1 u is equal to 1/12 the mass of one atom of carbon-12)
Molar mass (molar weight) is the mass of one mole of a substance and is expressed in g/mol.

Molarity Calculator

Mass Concentration Volume Molecular Weight

Clinical Trial Information

NCT Number Recruitment Conditions Sponsor/Collaborators Start Date Phases
NCT02520778 Recruiting EGFR Activating Mutation|Recurrent Non-Small Cell Lung Carcinoma|Stage III Non-Small Cell Lung Cancer|Stage IIIA Non-Small Cell Lung Cancer|Stage IIIB Non-Small Cell Lung Cancer|Stage IV Non-Small Cell Lung Cancer National Cancer Institute (NCI) March 2016 Phase 1
NCT02591095 Active, not recruiting Platinum-resistant or Refractory Ovarian Cancer Centre Francois Baclesse|ARCAGY/ GINECO GROUP|French Cancer Research Hospital Program January 2016 Phase 2
NCT02143401 Recruiting Recurrent Hepatocellular Carcinoma|Solid Neoplasm|Stage IV Hepatocellular Carcinoma National Cancer Institute (NCI) November 2014 Phase 1
NCT02079740 Recruiting Advanced Solid Neoplasm|KRAS Gene Mutation|Metastatic Solid Neoplasm|NRAS Gene Mutation|Recurrent Colorectal Carcinoma|Recurrent Lung Carcinoma|Recurrent Pancreatic Carcinoma|Stage III Colorectal Cancer|Stage III Lung Cancer|Stage III Pancreatic Cancer|Stage IIIA Colorectal Cancer|Stage IIIB Colorectal Cancer|Stage IIIC Colorectal Cancer|Stage IV Colorectal Cancer|Stage IV Lung Cancer|Stage IV Pancreatic Cancer|Stage IVA Colorectal Cancer|Stage IVB Colorectal Cancer National Cancer Institute (NCI) March 2014 Phase 1|Phase 2
NCT01989585 Recruiting Metastatic Melanoma|Recurrent Melanoma|Solid Neoplasm|Stage IIIA Skin Melanoma|Stage IIIB Skin Melanoma|Stage IIIC Skin Melanoma|Stage IV Skin Melanoma National Cancer Institute (NCI) October 2013 Phase 1|Phase 2
NCT01828476 Completed Prostate Cancer Rutgers, The State University of New Jersey|Rutgers Cancer Institute of New Jersey|National Cancer Institute (NCI)|AbbVie June 2013 Phase 2

Tech Support

Answers to questions you may have can be found in the inhibitor handling instructions. Topics include how to prepare stock solutions, how to store inhibitors, and issues that need special attention for cell-based assays and animal experiments.

Handling Instructions

Tel: +1-832-582-8158 Ext:3

If you have any other enquiries, please leave a message.

  • * Indicates a Required Field

Frequently Asked Questions

  • Question 1:

    I would like to deliver S1001 via i.p. injection, can you suggest a vehicle solution?

  • Answer:

    S1001 ABT-263 (Navitoclax) can be dissolved in 5% DMSO+corn oil at 7mg/ml as a clear solution.

  • Question 2:

    Could you tell me if the catalog number S1001 can go through the hemato-encephalic barrier?

  • Answer:

    According to the paper: http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3223694/, ABT-263 can not cross brain-blood barrier.

Related Antibodies

Bcl-2 Signaling Pathway Map

Bcl-2 Inhibitors with Unique Features

Related Bcl-2 Products

Tags: buy Navitoclax (ABT-263) | Navitoclax (ABT-263) supplier | purchase Navitoclax (ABT-263) | Navitoclax (ABT-263) cost | Navitoclax (ABT-263) manufacturer | order Navitoclax (ABT-263) | Navitoclax (ABT-263) distributor
×
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID